Aclarion names Daniel Keefe commercial director for western US
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/13/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Aclarion Appoints Daniel Keefe as Commercial Director, Western U.S., to Drive Continued Adoption of Nociscan
April 28, 2026 6:00 AM EDTCommercial leader with proven track record of driving growth, surgeon adoption, and market expansion with innovative spine and surgical technologiesExpansion of commercial team reflects increasing demand for Nociscan, supported by triple-digit growth in utilization
BROOMFIELD, Colo., April 28, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc. (Aclarion or the Company) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary... More
